RxDoctor Payments Data

Melissa Isbell, MD

Nephrology · San Antonio, TXNPI 1881660660

Payments from drug & device makers

$10,852in general payments, 2019–2025

Across 473 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$1K
  • Calliditas Therapeutics US Inc.$690
  • Bayer$629
  • Veloxis Pharmaceuticals, Inc.$602
  • Otsuka America Pharmaceutical, Inc.$494
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$10,56797%
  • Education$2853%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,852 in reported general payments places this provider in the 80th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$302,722
Medicare patients
510
Services billed
5,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CrysvitaBurosumab-Twza12$449,460
JynarqueTolvaptan11$212,711
FarxigaDapagliflozin Propanediol195$197,227
FilspariSparsentan11$134,092
MounjaroTirzepatide105$111,642
JardianceEmpagliflozin116$109,317
RayaldeeCalcifediol54$91,669
KerendiaFinerenone31$40,299
EliquisApixaban29$28,982
LokelmaSodium Zirconium Cyclosilicate32$28,766
VeltassaPatiromer Calcium Sorbitex17$20,687
TrulicityDulaglutide14$19,239
Envarsus XrTacrolimus30$18,770
TradjentaLinagliptin21$17,518
Cinacalcet Hcl39$16,419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kyowa Kirin, Inc.Crysvita$53$449,46012 claims
AstraZenecaFarxiga, Lokelma$2,318$225,993227 claims
Otsuka America Pharmaceutical, Inc.Jynarque$494$212,71111 claims
Travere Therapeutics, Inc.Filspari$289$134,09211 claims
Lilly USA, LLCMounjaro, Trulicity$492$130,881119 claims
Boehringer IngelheimJardiance, Tradjenta$126$126,835137 claims
OPKO Pharmaceuticals, LLCRayaldee$486$91,66954 claims
BayerKerendia$629$40,29931 claims
PfizerEliquis$22$28,98229 claims
Arbor Pharmaceuticals, Inc.Edarbi$59$8,15613 claims
ANI Pharmaceuticals, Inc.Valsartan$55$1,09323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,070 nephrology providers in Texas.

Other nephrology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →